HTG Molecular Diagnostics (NASDAQ:HTGM) received a $7.00 target price from stock analysts at HC Wainwright in a note issued to investors on Monday. The brokerage currently has a “buy” rating on the medical research company’s stock. HC Wainwright’s price objective indicates a potential upside of 99.43% from the company’s previous close.
Other equities analysts have also recently issued research reports about the stock. Zacks Investment Research raised shares of HTG Molecular Diagnostics from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a report on Wednesday, January 17th. Canaccord Genuity lifted their price target on HTG Molecular Diagnostics from $5.00 to $7.00 and gave the company a “buy” rating in a report on Friday, March 23rd. Finally, ValuEngine raised HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. HTG Molecular Diagnostics currently has a consensus rating of “Buy” and an average target price of $6.56.
Shares of NASDAQ HTGM opened at $3.51 on Monday. HTG Molecular Diagnostics has a 52-week low of $3.40 and a 52-week high of $3.50. The stock has a market capitalization of $100.43 million, a price-to-earnings ratio of -1.96 and a beta of 1.61.
HTG Molecular Diagnostics (NASDAQ:HTGM) last issued its earnings results on Thursday, May 10th. The medical research company reported ($0.22) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.26) by $0.04. The business had revenue of $4.16 million during the quarter, compared to the consensus estimate of $5.24 million. equities analysts expect that HTG Molecular Diagnostics will post -0.66 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in HTGM. New York State Common Retirement Fund bought a new stake in shares of HTG Molecular Diagnostics during the first quarter valued at approximately $170,000. Northern Trust Corp bought a new stake in shares of HTG Molecular Diagnostics during the first quarter valued at approximately $189,000. Stifel Financial Corp bought a new stake in shares of HTG Molecular Diagnostics during the first quarter valued at approximately $343,000. Finally, Private Wealth Partners LLC bought a new stake in shares of HTG Molecular Diagnostics during the fourth quarter valued at approximately $710,000. 8.38% of the stock is currently owned by institutional investors.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company's products, HTG Edge and HTG EdgeSeq platforms include instrumentation (or platforms), consumables comprising assay kits, and software analytics that automate sample processing and profiles various molecular targets from samples a fraction of the size required by prevailing technologies.
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.